. 2020 Oct 12;143(4):298–309. doi: 10.1161/CIRCULATIONAHA.120.050391
© 2020 The Authors.
Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Table 5.
Safety and Tolerability of Dapagliflozin by Baseline eGFR Group
